Ligand Pharmaceuticals (LGND) vs Supernus (SUPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ligand Pharmaceuticals (LGND) has outperformed Supernus (SUPN) over the past year, gaining 44.0% versus a loss of 36.9%. Over five years, LGND leads with a +193.2% price change compared with -6.5% for SUPN. Supernus is the larger company by market cap ($5.94 billion vs $5.74 billion), about 1.0 times the size, while Ligand Pharmaceuticals is growing revenue faster (+60.4% vs +8.6%).
On valuation, Supernus trades at a lower forward P/E (7.1x vs 24.0x for Ligand Pharmaceuticals). Ligand Pharmaceuticals converts more of its revenue into profit, with a net margin of 46.4% versus -5.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LGND | SUPN |
|---|---|---|
| Share price | $286.85 | $28.61 |
| Market cap | $5.74B | $5.94B |
| 1-day change | -0.03% | +0.92% |
| YTD return | +51.72% | -42.43% |
| 1-year return | +43.98% | -36.87% |
| 5-year return | +193.16% | -6.53% |
| P/E ratio (TTM) | 115.20 | — |
| Forward P/E | 24.00 | 7.15 |
| EPS (TTM) | $2.49 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $268.09M | $718.95M |
| Revenue growth (YoY) | +60.40% | +8.63% |
| Net income (latest FY) | $124.45M | $-38.55M |
| Gross margin | — | 89.63% |
| Operating margin | 15.29% | -8.66% |
| Net margin | 46.42% | -5.36% |
| 52-week high | $326.63 | $42.81 |
| 52-week low | $175.89 | $25.92 |
| Distance from 52-week high | -12.18% | -33.17% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +25.94% | +89.23% |
| Average volume | 230.79K | 2.77M |
| Shares outstanding | 20.00M | 207.72M |
| Employees | 47 | 827 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LGND has outperformed SUPN by 80.9 percentage points over the past year.
- Ligand Pharmaceuticals is more profitable, keeping 46.4 cents of every revenue dollar as net income versus -5.4 cents for Supernus.
- Ligand Pharmaceuticals grew revenue faster in its latest fiscal year (+60.40% vs +8.63%).
About Ligand Pharmaceuticals
LGND stock →Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 47 employees
About Supernus
SUPN stock →Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 827 employees
LGND vs SUPN FAQ
Which is bigger, Ligand Pharmaceuticals or Supernus?
Supernus (SUPN) is larger, with a market capitalization of $5.94B compared with $5.74B for Ligand Pharmaceuticals (LGND).
Which stock has performed better over the past year, LGND or SUPN?
LGND returned +43.98% over the past 12 months, compared with -36.87% for SUPN (price return, excluding dividends). Past performance does not predict future results.
Are Ligand Pharmaceuticals and Supernus in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.